...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients
【24h】

Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients

机译：心脏合并症是肺癌患者放射性肺毒性的独立危险因素

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose To test the hypothesis that cardiac comorbidity before the start of radiotherapy (RT) is associated with an increased risk of radiation-induced lung toxicity (RILT) in lung cancer patients. Material and methods A retrospective analysis was performed of a prospective cohort of 259 patients with locoregional lung cancer treated with definitive radio(chemo)therapy between 2007 and 2011 (ClinicalTrials.gov Identifiers: NCT00572325 and NCT00573040). We defined RILT as dyspnea CTCv.3.0 grade ≥2 within 6 months after RT, and cardiac comorbidity as a recorded treatment of a cardiac pathology at a cardiology department. Univariate and multivariate analyses, as well as external validation, were performed. The model-performance measure was the area under the receiver operating characteristic curve (AUC). Results Prior to RT, 75/259 (28.9%) patients had cardiac comorbidity, 44% of whom (33/75) developed RILT. The odds ratio of developing RILT for patients with cardiac comorbidity was 2.58 (p < 0.01). The cross-validated AUC of a model with cardiac comorbidity, tumor location, forced expiratory volume in 1 s, sequential chemotherapy and pretreatment dyspnea score was 0.72 (p < 0.001) on the training set, and 0.67 (p < 0.001) on the validation set. Conclusion Cardiac comorbidity is an important risk factor for developing RILT after definite radio(chemo)therapy of lung cancer patients.
机译：目的为了检验以下假设：在肺癌患者中，放疗开始前的心脏合并症与放疗引起的肺毒性（RILT）风险增加有关。材料和方法回顾性分析了2007年至2011年间接受放疗（化学）治疗的259例局部区域肺癌患者的前瞻性队列（ClinicalTrials.gov标识符：NCT00572325和NCT00573040）。我们将RILT定义为RT后6个月内呼吸困难CTCv.3.0≥2级，并将心脏合并症定义为心脏病科心脏病的记录治疗。进行了单变量和多变量分析以及外部验证。模型性能度量是接收器工作特性曲线（AUC）下的面积。结果在放疗前，有75/259（28.9％）的患者患有心脏合并症，其中44％（33/75）患有RILT。心脏合并症患者发生RILT的优势比为2.58（p <0.01）。交叉合并验证的具有心脏合并症，肿瘤位置，1秒内的呼气量，连续化疗和治疗前呼吸困难评分的模型在训练组上的AUC为0.72（p <0.001），在验证组上为0.67（p <0.001）组。结论心脏合并症是确定放疗后肺癌患者发生RILT的重要危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号